Home＞REGULATORY
Payer Rep Insists CEA-Based Price Hike “Not an Option,” MHLW Wants “Grounds” for That Argument: Chuikyo(Oct.26.2017)
Medical Economics Division Director Masami Sakoi Preparing for Chuikyo CEA Joint Meeting |
As a vocal payer member of a key reimbursement policy panel continues to stand against a possible price raise under an as-yet-elusive cost-effective assessment scheme in Japan, a health ministry official chafed at his refusal on October 25, asking for “grounds” for his argument ...
(LOG IN FOR FULL STORY)
-
- Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts Apr.23
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR Apr.20
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official Apr.19
- Generic Industry Asks for Govt Support for Continuous Manufacturing to Boost Int’l Competitiveness: Public-Private Confab Apr.17
- No Company Supports New Price Maintenance Premium Scheme: FPMAJ Survey Apr.17
- Japan Trains Sight on CEA as Centerpiece of This Year’s Cost Containment Efforts(Apr.23)
- Japan Ethical Drug Sales in 54 Fields Shrink 1.6% in 2017(Apr.23)
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020(Apr.23)
- Takeda Sweetens Bid for Shire, Ups Cash Component(Apr.23)
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
